LONDON, May 17: AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a rare type of leukemia as the group’s new CEO delivers on a promise to accelerate its oncology programs. Britain’s second-biggest drugmaker said on Thursday the Phase III clinical trial would test moxetumomab pasudotox in patients with hairy cell leukemia who have not responded to or have relapsed after standard therapy. (AGENCIES)
Trending Now
E-Paper
Follow our WhatsApp channel